Taking lipoic acid failed to ease progressive MS symptoms in a clinical trial, but the antioxidant showed signs of slowing ...

Lipoic acid offers no improvements in walking speed or other outcomes in patients with progressive multiple sclerosis ...

After menopause, women with multiple sclerosis experienced accelerated volume loss in global gray matter, the left hippocampus, and the left anterior cingulate, highlighting the menopausal transition ...

The over‐the‐counter supplement lipoic acid may have a small beneficial effect in slowing the loss of gray matter in the brains of people with progressive forms of multiple sclerosis, according to new ...

Brain volume loss is a key marker of degeneration in multiple sclerosis, correlated with future disability progression. Ponesimod, alemtuzumab, teriflunomide, ozanimod, and fingolimod significantly ...

Please provide your email address to receive an email when new articles are posted on . Obstructive sleep apnea and multiple sclerosis both increase atrophy of the brain’s gray and white matter.

The over-the-counter supplement lipoic acid may have a small beneficial effect in slowing the loss of gray matter in the brains of people with progressive forms of multiple sclerosis, according to new ...

A single dose of Immutep’s MS therapy, IMP761, was well tolerated and reduced T-cell activity for up to 23 days in healthy ...

October 20, 2011 (Amsterdam, the Netherlands) — A new investigation finds that 6 years after diagnosis, brain volumes and, particularly, cognition were more severely affected in men with multiple ...

New research reveals a strong link between persistent brain inflammation and early brain shrinkage in children with MS. These "hot spots" of inflammation, visible on advanced MRIs, can silently damage ...

This study demonstrated progressive CP enlargement over time in individuals with RRMS, averaging 1.4% a year with significant variation per participant. CP enlargement correlated with the expansion of ...

A cross-sectional, prospective study found that gray matter atrophy was more prevalent in patients with more severe progressive multiple sclerosis (MS) compared with those with less severe progressive ...